Clonal dissemination and resistance genes among <i>Stenotrophomonas maltophilia</i> in a Greek University Hospital during a four-year period

Matthaios Papadimitriou-Olivgeris; Fevronia Kolonitsiou; Maria Militsopoulou; Iris Spiliopoulou; Nikolaos Giormezis; Matthaios Papadimitriou-Olivgeris; Fevronia Kolonitsiou; Maria Militsopoulou; Iris Spiliopoulou; Nikolaos Giormezis

doi:10.3934/microbiol.2022021

AIMS Microbiology

2022, Volume 8, Issue 3: 292-299. doi: 10.3934/microbiol.2022021

Previous Article Next Article

Communication Special Issues

Clonal dissemination and resistance genes among Stenotrophomonas maltophilia in a Greek University Hospital during a four-year period

1.
Division of Infectious Diseases, School of Medicine, University of Patras, Patras, Greece
2.
Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland
3.
Department of Microbiology, School of Medicine, University of Patras, Patras, Greece

Received: 02 April 2022 Revised: 28 June 2022 Accepted: 29 June 2022 Published: 12 July 2022

Treatment of Stenotrophomonas maltophilia infections comprises of sulfamethoxazole/tripethoprim (SXT) or fluoroquinolones. We investigated antimicrobial resistance, presence of resistance genes (sul1, smqnr) and clonal dissemination in S. maltophilia from a university hospital. Among 62 isolates, 45 (73%) represented infection. Two isolates (3%) were resistant to SXT and three (5%) to levofloxacin. Twenty-nine isolates (47%), including two out of three levofloxacin-resistant, carried smqnr. Resistance of S. maltophilia was low and was not associated with sul1 or smqnr carriage. Although high degree of genetic diversity was identified (29 pulsotypes), 22/62 (35.5%) strains were classified into four clones; clone b was associated with bacteraemias.
- Stenotrophomonas maltophilia,
- resistance,
- infections,
- clones,
- bacteraemia
Citation: Matthaios Papadimitriou-Olivgeris, Fevronia Kolonitsiou, Maria Militsopoulou, Iris Spiliopoulou, Nikolaos Giormezis. Clonal dissemination and resistance genes among Stenotrophomonas maltophilia in a Greek University Hospital during a four-year period[J]. AIMS Microbiology, 2022, 8(3): 292-299. doi: 10.3934/microbiol.2022021

Related Papers:

Abstract

Treatment of Stenotrophomonas maltophilia infections comprises of sulfamethoxazole/tripethoprim (SXT) or fluoroquinolones. We investigated antimicrobial resistance, presence of resistance genes (sul1, smqnr) and clonal dissemination in S. maltophilia from a university hospital. Among 62 isolates, 45 (73%) represented infection. Two isolates (3%) were resistant to SXT and three (5%) to levofloxacin. Twenty-nine isolates (47%), including two out of three levofloxacin-resistant, carried smqnr. Resistance of S. maltophilia was low and was not associated with sul1 or smqnr carriage. Although high degree of genetic diversity was identified (29 pulsotypes), 22/62 (35.5%) strains were classified into four clones; clone b was associated with bacteraemias.

Conflict of interest

All authors declare no conflicts of interest in this paper.

References

[1]	Brooke JS (2012) Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25: 2-41. https://doi.org/10.1128/CMR.00019-11
[2]	Lai CH, Chi CY, Chen HP, et al. (2004) Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 37: 350-358. Available from: https://pubmed.ncbi.nlm.nih.gov/15599467/
[3]	Chang LL, Chen HF, Chang CY, et al. (2004) Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 53: 518-521. https://doi.org/10.1093/jac/dkh094
[4]	Hu LF, Chang X, Ye Y, et al. (2011) Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 37: 230-234. https://doi.org/10.1016/j.ijantimicag.2010.10.025
[5]	Malekan M, Tabaraie B, Akhoundtabar L, et al. (2017) Distribution of class I integron and smqnr resistance gene among stenotrophomonas maltophilia isolated from clinical samples in Iran. Avicenna J Med Biotechnol 9: 138-141. Available from: https://pubmed.ncbi.nlm.nih.gov/28706609/
[6]	(2020) Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing. CLSI supplement M100. PA: Wayne. Available from: https://www.clsi.org/standards/products/microbiology/documents/m100/
[7]	Bostanghadiri N, Ghalavand Z, Fallah F, et al. (2019) Characterization of phenotypic and genotypic diversity of Stenotrophomonas maltophilia strains isolated from selected hospitals in Iran. Front Microbiol 10: 1191. https://doi.org/10.3389/fmicb.2019.01191
[8]	Tenover FC, Arbeit RD, Goering RV, et al. (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33: 2233-2239. https://doi.org/10.1128/jcm.33.9.2233-2239.1995
[9]	Neela V, Rankouhi SZ, van Belkum A, et al. (2012) Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim-sulfamethoxazole resistance. Int J Infect Dis 16: e603-e607. https://doi.org/10.1016/j.ijid.2012.04.004
[10]	Song JH, Sung JY, Kwon KC, et al. (2010) Analysis of acquired resistance genes in Stenotrophomonas maltophilia. Korean J Lab Med 30: 295-300. https://doi.org/10.3343/kjlm.2010.30.3.295
[11]	Hu LF, Chen GS, Kong QX, et al. (2016) Increase in the prevalence of resistance determinants to trimethoprim/sulfamethoxazole in clinical Stenotrophomonas maltophilia isolates in China. PloS One 11: e0157693. https://doi.org/10.1371/journal.pone.0157693
[12]	Kanamori H, Yano H, Tanouchi A, et al. (2015) Prevalence of smqnr and plasmid-mediated quinolone resistance determinants in clinical isolates of Stenotrophomonas maltophilia from Japan: novel variants of Smqnr. New Microbes New Infect 7: 8-14. https://doi.org/10.1016/j.nmni.2015.04.009
[13]	Juhász E, Krizsán G, Lengyel G, et al. (2014) Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann Clin Microbiol Antimicrob 13: 333. https://doi.org/10.1186/s12941-014-0058-9
[14]	Ebrahim-Saraie HS, Heidari H, Soltani B, et al. (2019) Prevalence of antibiotic resistance and integrons, sul and Smqnr genes in clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in Southwest Iran. Iran J Basic Med Sc 22: 872-877. https://doi.org/10.22038/ijbms.2019.31291.7540
[15]	Kaur P, Gautam V, Tewari R (2015) Distribution of class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in North India. Microbial drug resistance (Larchmont,N.Y.) 21: 380-385. https://doi.org/10.1089/mdr.2014.0176
[16]	Kolonitsiou F, Papadimitriou-Olivgeris M, Spiliopoulou A, et al. (2017) Trends of bloodstream infections in a university greek hospital during a three-year period: Incidence of multidrug-resistant bacteria and seasonality in gram-negativep Predominance. Pol J Microbiol 66: 171-180. https://doi.org/10.5604/01.3001.0010.7834
[17]	European Centre for Disease Prevention and ControlPoint prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals (2013). https://doi.org/10.2807/ese.17.46.20316-en
[18]	Valdezate S, Vindel A, Martín-Dávila P, et al. (2004) High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital. J Clin Microbiol 42: 693-699. https://doi.org/10.1128/JCM.42.2.693-699.2003
[19]	Wang N, Tang C, Wang L (2022) Risk factors for acquired Stenotrophomonas maltophilia pneumonia in intensive care unit: A systematic review and meta-analysis. Front Med 8: 808391. https://doi.org/10.3389/fmed.2021.808391
[20]	Lin Q, Zou H, Chen X, et al. (2021) Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiol 21: 60. https://doi.org/10.1186/s12866-021-02108-2

Reader Comments

Your name:*

Email:*
© 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)